Kremsner: New malaria vaccine is '100 percent protective'
Research workers at the University of T? bingen have examined a new malaria immunization method that they believe to be 100 percent effective. Peter Kremsner informed BLOG what's special about the new vaccine.
BLOG: A fresh malaria immunization method that you tested on 67 healthy individuals was 100 %| successful in the first round of testing. Are these claims a breakthrough in decreasing malaria?
Peter Kremsner: All of us sure hope so. The success we had with the brand new strategy to malaria immunization shocked us, too.
New sumpffieber vaccines have been released quite frequently. What is different with regards to your results?
We got the living parasites and put them in a vaccine, which we then gave the individuals collectively with an anti-malaria medication. That drug is taken orally. The parasites get into the liver, but the illness only fractures out when they reach the bloodstream -which is where the anti-malaria medicine catches them. It weakens or kills the parasitic organisms so they really can't do any harm anymore.
What's the difference between might the vaccine RTS, S (Mosquirix), which was developed by the European Medicines Company (EMA) in 2015?
RTS, S contains parts of the malaria parasite's surface molecule and other added molecules. We on the other hand took the entire parasite and gave it to our test individuals with the anti-malaria medication to weaken the vermine. This is a new way of doing things. We transferred away from the antigens, which are parts of the molecules which may have recently been used for shot production against malaria and other diseases.
Kremsner in his lab at the University of T? bingen
Why does your method work?
An active element like Mosquirix uses just one part of a molecule. It's a very important one, but still, it may recognize only one part of the vermine as well. Results have shown that Mosquirix worked in just 30 to 60 percent of cases. This was also a breakthrough discovery, because it was the first ever anti-parasite shot against malaria which can be used in humans. But it still wasn't enough for us.
With all the vaccine using the complete cell, we have the opportunity that lots of different molecules are identified by the immune system at an early stage. The malaria parasite molecules then trigger an immune response which, as we have shown, is 100 % defensive.
How exactly did your trial work?
Our individuals were young, healthy bingen residents who never had malaria before. We injected them with the malaria parasites and gave them the anti-malaria drug simultaneously. We examined this in numerous stages, with different dosages and various time spans in between the injections. It worked well when the individuals were injected with a dosage of 50,500 parasites and took the malaria drug at the same time.
This is the first study of it's kind. Of course the number of participants is small. Yet we could protect seven out of nine individuals in each of our trial groups with this kind of immunization. That is a major breakthrough and we will continue to work on it.
We're researching other anti-malaria drugs that may work even better. We're trying out the dosage and enough time frame to see if you could take it for a shorter time so it'll improve travel medication. Mostly we're working on injecting both the vaccine and the anti-malaria drug together with the same syringe. There already are anti-malaria drugs that are given intravenously.
Research workers at the University of T? bingen have examined a new malaria immunization method that they believe to be 100 percent effective. Peter Kremsner informed BLOG what's special about the new vaccine.
BLOG: A fresh malaria immunization method that you tested on 67 healthy individuals was 100 %| successful in the first round of testing. Are these claims a breakthrough in decreasing malaria?
Peter Kremsner: All of us sure hope so. The success we had with the brand new strategy to malaria immunization shocked us, too.
New sumpffieber vaccines have been released quite frequently. What is different with regards to your results?
We got the living parasites and put them in a vaccine, which we then gave the individuals collectively with an anti-malaria medication. That drug is taken orally. The parasites get into the liver, but the illness only fractures out when they reach the bloodstream -which is where the anti-malaria medicine catches them. It weakens or kills the parasitic organisms so they really can't do any harm anymore.
What's the difference between might the vaccine RTS, S (Mosquirix), which was developed by the European Medicines Company (EMA) in 2015?
RTS, S contains parts of the malaria parasite's surface molecule and other added molecules. We on the other hand took the entire parasite and gave it to our test individuals with the anti-malaria medication to weaken the vermine. This is a new way of doing things. We transferred away from the antigens, which are parts of the molecules which may have recently been used for shot production against malaria and other diseases.
Kremsner in his lab at the University of T? bingen
Why does your method work?
An active element like Mosquirix uses just one part of a molecule. It's a very important one, but still, it may recognize only one part of the vermine as well. Results have shown that Mosquirix worked in just 30 to 60 percent of cases. This was also a breakthrough discovery, because it was the first ever anti-parasite shot against malaria which can be used in humans. But it still wasn't enough for us.
With all the vaccine using the complete cell, we have the opportunity that lots of different molecules are identified by the immune system at an early stage. The malaria parasite molecules then trigger an immune response which, as we have shown, is 100 % defensive.
How exactly did your trial work?
Our individuals were young, healthy bingen residents who never had malaria before. We injected them with the malaria parasites and gave them the anti-malaria drug simultaneously. We examined this in numerous stages, with different dosages and various time spans in between the injections. It worked well when the individuals were injected with a dosage of 50,500 parasites and took the malaria drug at the same time.
This is the first study of it's kind. Of course the number of participants is small. Yet we could protect seven out of nine individuals in each of our trial groups with this kind of immunization. That is a major breakthrough and we will continue to work on it.
We're researching other anti-malaria drugs that may work even better. We're trying out the dosage and enough time frame to see if you could take it for a shorter time so it'll improve travel medication. Mostly we're working on injecting both the vaccine and the anti-malaria drug together with the same syringe. There already are anti-malaria drugs that are given intravenously.
No comments:
Post a Comment